Form 4: Wave Life Sciences Director Acquires Shares and Options Under Compensation Policy

Director Aik Na Tan acquired shares and options in Wave Life Sciences Ltd. under the 2024 Non-Employee Director Compensation Policy.

Summary

• On August 12, 2024, Aik Na Tan, a director of Wave Life Sciences Ltd., acquired 16,115 ordinary shares and options for 32,230 shares.
• The shares were granted as a restricted share unit (RSU) award, and the options were granted pursuant to the 2024 Non-Employee Director Compensation Policy.
• The RSU and options vest 100% on the earlier of the company's 2025 annual general meeting or August 12, 2025.
• Following the transaction, Tan directly owns 16,115 ordinary shares and options for 32,230 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard director compensation practices, indicating confidence in the company's future.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted shares and options.

Industry Context

This type of filing is standard for publicly traded companies and reflects compensation practices for non-employee directors.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash, stock options, and restricted stock units (RSUs).
• The vesting schedule of one year is fairly standard for director equity grants.
• Comparing the size of the grant to similar biotech companies would provide further context on the competitiveness of the compensation package.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Next Steps

• The shares and options will vest on the earlier of the company's 2025 annual general meeting or August 12, 2025.

Key Dates